linjc16/ctgov huggingface dataset:
Automatic Real-time Diagnosis of Gastric Mucosal Disease Using pCLE With Artificial Intelligence

Study Overview
=================
Brief Summary
-----------------
Probe-based confocal laser endomicroscopy (pCLE) is an endoscopic technique that enables real-time histological evaluation of gastric mucosal disease during ongoing endoscopy examination. However this requires much experience, which limits the application of pCLE. The investigators designed a computer-aided diagnosis program using deep neural network to make diagnosis automatically in pCLE examination and contrast its performance with endoscopists.

Official Title
-----------------
Automatic Real-time Diagnosis of Gastric Mucosal Disease Using Probe-based Confocal Laser Endomicroscopy With Artificial Intelligence

Conditions
-----------------
Gastric Diseases, Artificial Intelligence, Confocal Laser Endomicroscopy

Intervention / Treatment
-----------------
* Diagnostic Test: The diagnosis of Artificial Intelligence and endoscopist


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged between 18 and 80; agree to give written informed consent. Exclusion Criteria: Patients under conditions unsuitable for performing CLE including coagulopathy , impaired renal or hepatic function, pregnancy or breastfeeding, and known allergy to fluorescein sodium; Inability to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| lesions observed by pCLE<br>pCLE is used to distinguish the suspected lesions detected by white light endoscopy. | Diagnostic Test: The diagnosis of Artificial Intelligence and endoscopist<br>* When suspected lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The diagnosis efficiency of Artificial Intelligence | The primary outcome is to test the diagnostic accuracy, sensitivity, specificity, PPV, NPV of the Artificial Intelligence for diagnosing gastric mucosal disease on real-time pCLE examination. | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Contrast the diagnosis efficiency of Artificial Intelligence with endoscopists | The secondary outcome is to compare the diagnosis efficiency (including diagnostic accuracy, sensitivity, specificity, PPV, NPV for diagnosing gastric mucosal disease on real-time pCLE examination) between Artificial Intelligence and endoscopists. | 24 months |
Anti Vitamin K Therapeutic Education

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to measure the INR (International Normalized Ratio) time percentage in the target zone (TTR: time in therapeutic range) of children benefiting from the AVK therapeutic education program.

Official Title
-----------------
Anti Vitamin K Therapeutic Education With INR Self Measure Device Within Children From 0 to 18 Years

Conditions
-----------------
Cardio-vascular Diseases

Intervention / Treatment
-----------------
* Other: therapeutic education program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age from 0 to 18 years AVK prescription to accept participating to AVK therapeutic education program informed consent form of parents or legal person Exclusion Criteria: parents or legal person refusal to enter in the AVK therapeutic education

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AVK<br>patient with AVK treatment | Other: therapeutic education program<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| INR (International Normalized Ratio) time percentage in the target zone (TTR: time in therapeutic range) |  | up to 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life questionnaire |  | 2 years |
Evaluation of the Use of a Biodegradable Endoprothesis in the Prevention of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis

Study Overview
=================
Brief Summary
-----------------
The use of an endoprothesis in a pancreatic duct is a measure to minimize the incidence and severity of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis. In this study we will evaluate the use of a Biodegradable Endoprothesis: Archimede Fast Biodegradable Pancreatic Stent in patients with high risk of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis.The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography. The efficacy and the security of the device will be evaluated.

Official Title
-----------------
Prospective Evaluation of the Use of a Biodegradable Endoprothesis in the Prevention of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis

Conditions
-----------------
Obstructive Jaundice, Biliary Stricture, Sphincter of Oddi Dysfunction

Intervention / Treatment
-----------------
* Device: Placement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age>18 years Patients at risk of developing a Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis (procedure and/or patient-related risk factors Exclusion Criteria: Pregnant or breastfeeding women Recent diagnosis (<1 month) of acute pancreatitis contraindication to endoscopy Hypersensitivity to indomethacine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Prophylactic biodegradable pancreatic stent placement<br> | Device: Placement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography<br>* The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients with a complete clearance of the biodegradable stent | The degradation of the stent will be evaluated both duodenoscopy/fluoroscopy and endoscopy 15 days after its placement | Day 15 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biodegradable stent, Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis
Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.

Official Title
-----------------
Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis in Adults

Conditions
-----------------
Primary Axillary Hyperhidrosis

Intervention / Treatment
-----------------
* Biological: ANT-1403
* Biological: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ages 18 - 70 years of age diagnosis of moderate to severe primary axillary hyperhidrosis ≥50 mg of sweat production/axilla in 5 minutes as measured gravimetrically HDSS score of ≥3 Exclusion Criteria: diagnosis of secondary hyperhidrosis skin affliction in the axilla requiring medical treatment 20% aluminum hydrochloride, e.g. Drysol®, in 2 weeks prior of Baseline oral anticholinergic treatment botulinum toxin treatment in the prior 9 months history of surgery for axillary hyperhidrosis present or history of neuromuscular disease female subjects who are pregnant or are nursing a child

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active<br>ANT-1403 | Biological: ANT-1403<br> <br> |
| Placebo Comparator: Vehicle<br>Vehicle | Biological: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HDSS |  | Week 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GSP |  | Week 8 |
EP-Catheter Guided CS-Lead Implantation

Study Overview
=================
Brief Summary
-----------------
In patients undergoing CRT device implantation a lead positioning in the coronary sinus is required. Even this part of the surgical procedure is challenging. In this study we compared retrospectively to methods of CS-lead implantation: conventional vs. EP-catheter guided.

Official Title
-----------------
Conventional Versus EP-Catheter Guided Implantation of Coronary Sinus Lead in Patients Undergoing Cardiac Resynchronization Therapy

Conditions
-----------------
Heart Failure, Reduced Left Ventricular Ejection Fraction, Left Bundle Branch Block

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CRT implantation due to heart failure full documented data Exclusion Criteria: previous pacemaker/ICD/CRT implantation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Conventional group<br>In this group CS lead was implanted in a conventional manner. | |
| EP-catheter group<br>In this group coronary sinus was canulated using a steerable electrophysiology catheter. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Fluoroscopy Time | During CRT device implantation fluoroscopy is used and the total fluoroscopy time is counted. | During implantation | 
| Contrast medium account | contrast medium is used and counted during crt device implantation. | During surgical procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful implantation | Successful crt implantation was defined as effective positioning of RV and CS lead +/- right atrial lead. | During surgical procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
heart failure, cardiac resynchronization therapy, coronary sinus lead
Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma

Study Overview
=================
Brief Summary
-----------------
Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.

Official Title
-----------------
Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma

Conditions
-----------------
Ovarian Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Pre-Inclusion Criteria: - Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (CT) Inclusion Criteria: Pathological ovarian carcinoma diagnosed at pathological analysis after surgery. Neo adjuvant chemotherapy Exclusion Criteria: no neo-adjuvant chemotherapy no ovarian carcinoma at final pathological analysis less than 18 years old.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between cleaved FasL level ans neoadjuvant chemotherapy tumor response | Main outcome is cleaved FasL level and correlation with neoadjuvant chemotherapy tumor response, evaluated during surgery. | surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of tumoral T cells | Identification of tumoral T cells with FACS analysis of dissociated tumor. Different T cells will be studies: Treg/Th17/Th1/Th2 using antibodies against: CD45/CD3/CD4/CD25/FOXP3 (Treg), CD45/CD3/CD4/IL17A (Th17), CD45/CD3/CD4/CD8/IL4/INF (TCD8 and LTCD4 Th1 et Th2). | surgery | 
| Disease Free Survival rate |  | 18 months after surgery | 
| Overall survival rate |  | 18 months after surgery |
Effect of Hemodialysis Membranes on Platelet Count

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if there is a drop in platelet count after hemodialysis. Hemodialysis membranes are known to activate complement and cause a drop in platelets and sometimes in white blood cells. The investigators are going to study one of the membranes which is the Fresenius Optiflux® to check if it causes a drop in platelets.

Official Title
-----------------
Effect of Hemodialysis Membranes on Platelet Count

Conditions
-----------------
Thrombocytopenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients on Hemodialysis for >=6 months Exclusion Criteria: Hematological Cancers Myelodysplastic syndromes Baseline thrombocytopenia Acute infections (patients on antibiotics) Patients with Immune thrombocytopenic purpura (ITP)/Thrombotic thrombocytopenic purpura (TTP) HIV Liver disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drop in platelet counts |  | 90 minutes through hemodialysis and immediately after finishing hemodialysis |
Succinylcholine or Rocuronium for Rigid Bronchoscopy Under General Anesthesia

Study Overview
=================
Brief Summary
-----------------
Myorelaxation is generally used as a part of general anesthesia for interventional rigid bronchoscopy. Succinylcholine is most often used because its short duration of action but rocuronium can be used since sugammadex permits a rapid and complete reversal of the neuromuscular block. The aim of ths study is to compare both agents.

Official Title
-----------------
Interventional Rigid Bronchoscopy Under General Anesthesia: Influence of the Muscle Relaxant, Succinylcholine or Rocuronium, on the Quality of the Surgical Procedure

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Drug: succinylcholine
* Drug: rocuronium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients scheduled for an interventional rigid bronchoscopy under general anesthesia Exclusion Criteria: pregnant woman or woman of childbearing age, morbid obesity, drug allergy,contra-indication to succinylcholine, rocuronium, sugammadex, propofol, remifentanil, history of central neurological or brain damage, psychotropic treatment, pacemaker, renal failure, disease of the neuromuscular junction.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: succinylcholine<br>Succinylcholine 1 mg/kg and a second dose if necessary. | Drug: succinylcholine<br>* Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue<br>|
| Experimental: Rocuronium<br>rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary | Drug: rocuronium<br>* rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score of quality of the surgical procedure | The quality of the surgical procedure is evaluated by the surgeon (composite score) who is unaware of the neuromuscular agent used (see Fuchs-Buder et al. Acta Anaesthesiol Scand 2007;51(7):789-808) | one day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score of quality of anesthesia | The quality of anesthesia is evaluated by the anesthesist in charge on a scale 0-30 (0-10 for the induction ; 0-10 for maintenance; 0-10 for recovery) | one day |
Online Support Groups for Depression and Anxiety

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effectiveness of online support groups for anxiety and depression.

Detailed Description
-----------------
In recent years the number of online support groups for conditions like depression and anxiety has grown rapidly. Millions of people are thought to be using them around the world. This research aims to help find out whether the use of online support groups is beneficial and to learn more about what happens in these groups. This research will compare online support groups with expressive writing. Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time. In online support groups giving and receiving support from others can be helpful while expressive writing about emotional issues can be cathartic. 1,000 participants will be recruited online from the UK, USA and Canada and randomly assigned to either an existing online support group or to an expressive writing condition.

Official Title
-----------------
Randomised Controlled Trial of an Existing Online Support Group for Depression and Anxiety

Conditions
-----------------
Anxiety, Depression

Intervention / Treatment
-----------------
* Behavioral: Online support group
* Behavioral: Expressive writing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Self-defined depression & anxiety Resident in the UK, US or Canada Access to the internet Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Online support group<br> | Behavioral: Online support group<br>* Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time.<br>|
| Active Comparator: Expressive writing<br> | Behavioral: Expressive writing<br>* Online support groups are internet forums where like-minded people give and receive both informational and emotional support.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Center for Epidemiological Studies Depression Scale |  | Zero, three and six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction with Life Scale |  | Zero, three and six months | 
| The Medical Outcomes Study Social Support Survey |  | Zero, three and six months | 
| Generalised Anxiety Disorder Assessment |  | Zero, three and six months | 
| The Illness perception questionnaire |  | Zero, three and six months |